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Abstract
The purpose of this study was to clarify the mechanism responsible for the transcriptional
regulation of the mouse Col5a3 gene in osteoblastic cells. Transient transfection into rat osteosar-
coma ROS17/2.8 cells demonstrated that a region from nucleotides 337 to 1 was involved in the
transcriptional activity of the Col5a3 gene. An electrophoretic mobility shift assay showed that
Sp1/Sp3 and CBF/NF-Y bound to a GC-rich domain (194/186) and a CCAAT box (134/130) in
the Col5a3 gene, respectively. Introduction of mutations or deletion into a GC-rich domain, the
CCAAT box, or both elements decreased the transcription activity. Overexpression of Sp1 in-
creases the transcription activity and interferes with Sp family binding to the GC-rich domain to
decrease promoter activity. Therefore, the transcription of the mouse Col5a3 gene is cooperatively
regulated by Sp1 and CBF/NF-Y in osteoblastic cells.
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The purpose of this study was to clarify the mechanism responsible for the transcriptional regulation 
of the mouse Col5a3 gene in osteoblastic cells.  Transient transfection into rat osteosarcoma 
ROS17/2.8 cells demonstrated that a region from nucleotides －337 to ＋1 was involved in the transcrip-
tional activity of the Col5a3 gene.  An electrophoretic mobility shift assay showed that Sp1/Sp3 and 
CBF/NF-Y bound to a GC-rich domain (－194/－186) and a CCAAT box (－134/－130) in the Col5a3 
gene,  respectively.  Introduction of mutations or deletion into a GC-rich domain,  the CCAAT box,  or 
both elements decreased the transcription activity.  Overexpression of Sp1 increases the transcription 
activity and interferes with Sp family binding to the GC-rich domain to decrease promoter activity.  
Therefore,  the transcription of the mouse Col5a3 gene is cooperatively regulated by Sp1 and CBF/
NF-Y in osteoblastic cells
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ertebrate collagens,  a large family of extracel-
lular proteins,  are crucial to the formation and 
function of virtually every organ system [1].  Among 
them,  ﬁbrillar collagen,  which includes ﬁve molecular 
types (I,  II,  III,  V,  and XI),  participates in the for-
mation of ﬁbrils with molecules packed in quarter-
staggered arrays [2].  The ﬁbrillar collagens are 
divided into major types (I-III) and minor types (V and 
XI) based on their relative expression levels.  Minor 
ﬁbrillar collagen types V and XI are incorporated into 
the ﬁbrils of the much more abundant collagen types I 
and II,  respectively,  and act as regulators of the sizes 
and shapes of the resultant heterotypic ﬁbrils [3-7].
　 Type V collagen is broadly distributed in type I 
collagen-containing tissues as a heterotrimer [α1(V)]2
α2(V) and is found in a limited number of cell types 
and tissues as a rare [α1(V)]3 homotrimer.  The for-
mer regulates the physical properties of type I/V 
heterotypic collagen ﬁbrils via partially processed 
NH2-terminal globular sequences [5].  Defects in the 
human COL5A1 and COL5A2 genes underlie at least 
half of the cases of classic Ehlers-Danlos syndrome 
[8-10],  and the complete dependence of ﬁbril forma-
tion on type V collagen is indicative of the critical role 
in early ﬁbril initiation [11].  In addition to the 
[α1(V)]2α2(V) and [α1(V)]3 isoforms,  a relatively 
uncharacterized α1(V)α2(V)α3(V) heterotrimer has 
been isolated from human placenta and has also been 
reported in the uterus,  skin,  and synovial membranes 
[12-14].  The detection of α3(V) expression in nascent 
ligamentous attachments of developing joints,  mem-
branous linings of developing skeletal muscles,  and in 
V
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developing and regenerating peripheral nerves in 
mouse and rat suggests roles for the α1(V)α2(V)α3(V) 
heterotrimer in these tissues as well [15,  16].  The 
N-terminal globular domain of the pro-α3(V) chain 
inﬂuences bone formation by osteoblasts through pro-
teoglycans on the cell surface during development or 
regeneration [17].
　 The promoter of the human COL5A1 gene has been 
characterized.  A minimal promoter region within 212 
bp immediately upstream of the major transcriptional 
start site contains the region where Sp1 binds.  
Furthermore,  GAGA boxes in the promoter and the 
ﬁrst exon may aﬀect the level of transcription [18].  
In the mouse Col5a1 gene,  CBF/NF-Y binds to the 
CCAAT-like,  CAAAT sequence,  and activates the 
gene [19].  The COL5A2 gene depends on a cis-acting 
element that contains 2 contiguous protein binding 
sites,  FPA and FPB,  located between nucleotides 
－149 and －95bp [20].  Combinatorial interactions 
among PBX and PREP or HOX proteins are involved 
in regulating tissue-speciﬁc production of collagen V 
[21].
　 The sequences of human and mouse full-length pro-
α3(V) chains were determined [15].  These were 
closely related to the pro-α1(V) chain.  The core pro-
moter of COL5A3 was characterized,  thus demon-
strating that CBF/NF-Y acts as a transcriptional 
activator of COL5A3 in a human schwannoma cell line 
[22].  The present study characterized the proximal 
promoter of the mouse Col5a3 gene using ostoblastic 
cell lines.  The expression of the mouse Col5a3 gene 
was regulated through the GC-rich domain as well as 
through the CCAAT box in osteoblastic cells,  and the 
Sp1 was responsible for the up-regulation in combina-
tion with CBF/NF-Y.
Materials and Methods
　 Cells and cell culture conditions. The cell 
lines used in this study were rat ROS17/2.8 osteosar-
coma cells,  rat RCS chondrosarcoma cells,  and mouse 
preosteoblast MC3T3-E1 cells.  Cells were cultured 
in Dulbeccoʼs modiﬁed Eagleʼs medium containing 10ｵ 
heat-inactivated fetal bovine serum (Sanko Junyaku,  
Tokyo,  Japan) at 37℃ in a 5ｵ CO2/air environment.
　 Isolation of RNA. Total RNA was isolated 
from cultured cells using Isogen (Nippon Gene,  Tokyo,  
Japan) according to the manufacturerʼs instructions.  
RNA was quantiﬁed by optical density (A260) and 
stored at －80℃ until used.
　 Reverse transcription-polymerase chain reac-
tion (RT-PCR). The expression levels of Col5a3,  
Sp1,  and Sp3 mRNA in various cell lines were inves-
tigated by RT-PCR.  Three micrograms of total RNA 
was reverse transcribed by random hexamer priming 
using SuperScript II reverse transcriptase (Invit-
rogen,  Carlsbad,  CA,  USA).  The single-stranded 
cDNA was ampliﬁed by PCR using speciﬁc primer 
pairs (Table 1).  PCR was carried out for 30 cycles 
using a step cycle of 94℃ for 30sec,  55℃ for 
30sec,  72℃ for 30sec,  followed by 72℃ for 7min.  
The PCR products were analyzed by electrophoresis 
on a 1.5ｵ ethidium bromide-stained agarose gel.  The 
ampliﬁed fragment was eluted from the gel and 
sequenced.
　 Real-time RT-PCR. For a quantitative analy-
sis of the expression level of Col5a3 mRNA,  real-time 
PCR was performed using a LightCycler TaqMan 
Master (Roche,  Indianapolis,  IN,  USA).  The ther-
mal cycling conditions included 1 cycle at 95℃ for 
10min,  and 45 cycles at 95℃ for 10sec and at 60℃ 
for 30sec.  The relative mRNA expression level of 
Col5a1 was normalized against that of the GAPDH 
gene from the same RNA preparations using a com-
parative threshold cycle method.  The primer 
sequences are listed in Table 1.
　 Oligo-nucleotide-capping rapid ampliﬁcation 
of cDNA ends (RACE). To determine the tran-
scriptional start sites,  oligo-nucleotide-capping RACE 
was performed using the GeneRacer kit according to 
the manufacturerʼs protocol (Invitrogen) with the 
Col5a3-speciﬁc primers.  Ampliﬁcation products were 
subcloned into pGEM-T Easy Vector (Promega,  
Madison,  WI,  USA) for sequencing.
　 Construction of chimeric plasmids. To 
generate the 5ʼ stepwise deletion constructs,  PCR 
procedures were applied.  PCR was performed using 
sets of oligonucleotide primers that are SacI site-
linked 5ʼ and XhoI site-linked 3ʼ primers speciﬁc to the 
Col5a3 sequence (Table 1) and the BAC genomic 
plasmid RP23-349D13 as a template.  These PCR 
products were subcloned into the pGEM-T Easy vec-
tor,  followed by digestion with SacI and XhoI,  and 
subcloned into the SacI/XhoI site of the pGL4.10-
Basic vector (Promega).  Internal deletion and substi-
tution mutation constructs were generated by site-
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directed mutagenesis using the pGL4.10 －337/＋92 
plasmid as a template.  The PCR products were 
digested with endonuclease,  followed by self-ligation.  
All mutagenesis plasmids were digested with SacI and 
XhoI and then re-cloned into the SacI/XhoI I site of 
the pGL4.10-Basic vector.
　 The pCMV-Sp1,  PRC/CMV-Sp3 expression plas-
mid and the dominant-negative CBF-B/NF-YA were 
previously described [23-25].
　 Transient transfection and luciferase assays.
Transient transfection experiments were carried out 
using ROS17/2.8,  MC3T3-E1,  and RCS cells.  The 
cells were plated at a density of 2×105 per 35-mm 
dish 18h before transfection.  For transient transfec-
tion,  0.5µg of plasmid DNA was transfected into these 
cells by using calcium phosphate precipitation methods 
[26].  Plasmid pRL-TK vector (Promega) was always 
cotransfected as an internal control for transfection 
eﬃciency.  After additional cultivation for 48h,  the 
transfected cells were harvested,  lysed,  centrifuged 
to pellet the debris,  and subjected to luciferase assay.  
The luciferase activities were measured as chemilumi-
nescence in a luminometer (Lumat LB 9507,  Perkin-
Elmer Life Sciences,  Waltham,  MA,  USA) using the 
Dual Luciferase Reporter Assay System (Promega) 
according to the manufacturerʼs protocol.  The 
cotransfection experiments were performed using 
1.5µg of Sp1or Sp3 expression plasmids or 1.5µg of 
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Table 1　 Primers used for PCR procedures
1. For RT-PCR
　 Col5a3 (BC138419): (sense) 5ʼ-gatgaaccagaaacccctgc-3ʼ
(antisense) 5ʼ-agcaccaggaaagatctgga-3ʼ
　 Sp1 (AB077988): (sense) 5ʼ-agtgcagcaggatggttctg-3ʼ
(antisense) 5ʼ-taaagttcataattcccatg-3ʼ
　 Sp3 (AY902330): (sense) 5ʼ-ttcagatcattcctggctct-3ʼ
(antisense) 5ʼ-aggcaactgtgatgaagagg-3ʼ
　 β-actin (X03672): (sense) 5ʼ-aagagaggtatcctgaccct-3ʼ
(antisense) 5ʼ-tacattggctggggtgttgaa-3
2. For real time RT-PCR
　 Col5a3 (BC138419): (sense) 5ʼ-cggggaggagtcttttgag-3ʼ
(antisense) 5ʼ-gcctgagggtctggaattaac-3ʼ
　 GAPDH (BC145812): (sense) 5ʼ-caatgaatacggctacagcaac-3ʼ
(antisense) 5ʼ-ttactccttggaggccatgt-3ʼ
3. For generation of luciferase constructs of 5ʼ stepwise deletion (AC170598)
　 －1824/＋92: (sense; －1824) 5ʼ-atgagctcgggctccacccccttctc-3ʼ
　 －1509/＋92: (sense; －1509) 5ʼ-atgagctctggagatgaagagcttgg-3ʼ
　 －1209/＋92: (sense; －1209) 5ʼ-atgagctcaggtccaggttcaacgag-3ʼ
　　－909/＋92: (sense; －909) 5ʼ-atgagctccggcttctcaaagggcag-3ʼ
　　－609/＋92: (sense; －609) 5ʼ-atgagctcgggctatacagagaaacc-3ʼ
　　－337/＋92: (sense; －337) 5ʼ-atgagctcggtctgagacagaactca-3ʼ
　　－141/＋92: (sense; －141) 5ʼ-atgagctccagccagccaatagcgc-3ʼ
　　 －59/＋92: (sense; －59) 5ʼ-atgagctccgggccccgcccgcaag-3ʼ
　　　－9/＋92: (sense; －9) 5ʼ-atgagctcgtctcgggcagtctccag-3ʼ
　　　＋1/＋92: (sense; ＋1) 5ʼ-atgagctcagtctccagcagatcctc-3ʼ
　　　 Common: (antisense; ＋92) 5ʼ-atctcgagcctggtgcaccaaggcca-3ʼ
　 (The bold letters indicate the tagged SacI and XhoI sites in the sense and antisense primers for cloning.)
4. For CHIP assay (AC170598)
　 P1: (sense) 5ʼ-ttaagtgcctcttcttgctgagc-3ʼ
　 P2: (antisense) 5ʼ-gcgggggcgggaggggggaccca-3ʼ
　 P3: (sense) 5ʼ-tagatatgtgccaccacaactgt-3ʼ
　 P4: (antisense) 5ʼ-acgtcagatcccctcggagctggg-3ʼ
　 P5: (sense) 5ʼ-agcaggacctggctcttccaaga-3ʼ
　 P6: (antisense) 5ʼ-gactggttttatcaccttctaac-3ʼ
The accession number is shown in the parentheses.
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the dominant-negative CBF/NF-Y plasmid.  Mithra-
mycin A (Sigma,  St Louis,  MO,  USA) was incubated 
with a concentration of 100nM for 24h before the 
luciferase assays.  All transfections were repeated in 
triplicate and the results were expressed as the mean 
± S.D.  of four independent experiments.
　 Preparation of nuclear extracts. Nuclear 
extracts from ROS17/2.8 cells were prepared accord-
ing to the method of Dignam et al.  [27].  Brieﬂy,  
ROS17/2.8 cells,  1×108,  were scraped in ice-cold 
phosphate-buﬀered saline (PBS),  centrifuged for 
5min at 1,500×g,  and washed with PBS before being 
recentrifuged.  The pellets were resuspended in buﬀer 
(10mM HEPES,  pH7.8,  10mM KCl,  0.1mM 
EDTA,  0.1ｵ Nonidet P-40),  incubated on ice for 
10min,  and homogenized.  Nuclei were pelleted by 
centrifugation at 3,000×g for 10min at 4℃,  followed 
by resuspension in buﬀer (50mM HEPES,  pH7.8,  
420mM KCl,  5mM MgCl2,  0.1mM EDTA,  20ｵ 
glycerol) and mixed by rotation at 4℃ for 1h.  After 
centrifugation at 24,000×g for 30min at 4℃,  the 
supernatants were collected and stored at －80℃ 
until used.  The protein concentration of the nuclear 
extracts was determined by the Bradford assay (Bio-
Rad Laboratories,  Hercules,  CA,  USA) using bovine 
serum albumin as a standard.
　 Electrophoretic mobility shift assay (EMSA).
Wild-type and mutant probes used for EMSA were 
generated by PCR using each set of HindIII site-linked 
primers,  and all PCR products were subcloned into 
the pGEM-T Easy vector.  All plasmids were digested 
with HindIII,  and the digested fragments were radio-
labeled with [α-32P] dCTP using the Klenow fragment 
to ﬁll in the HindIII overhanging sites.  The binding 
reaction was carried out for 30min at 25℃ in 25µl of 
binding buﬀer (50mM HEPES,  pH7.8,  250mM KCl,  
25mM MgCl2,  5mM EDTA,  50ｵ glycerol) contain-
ing 20,000-30,000 cpm of labeled probe,  3µg of 
poly(dI-dC),  2µg of ssDNA,  and 5-15µg of nuclear 
extracts.  For the competition assays,  double-stranded 
oligonucleotides containing a consensus CBF/NF-Y,  
CBF/NF-Y mutant,  Sp1,  and Sp1 mutant binding 
sites were generated by annealing equimolar comple-
mentary oligonucleotides.  For the supershift assay,  
anti-CBF-A/NF-YB,  anti-CBF-B/NF-YA,  anti-
CBF-C/NF-YC,  anti-Sp1,  and anti-Sp3 polyclonal 
antibodies were purchased (Santa Cruz Biotechnology,  
Santa Cruz,  CA,  USA).  For these interference 
assays,  a 5 to 100-fold molar excess of unlabeled 
competitor or 2µg of antibody was added to the reac-
tion mixture for 1h at 4℃ before the addition of the 
radiolabeled probe.  The DNA-protein complexes were 
separated on a 4.5ｵ non-denaturing polyacrylamide 
gel in a 0.25× Tris borate electrophoresis buﬀer at 
200 V.  After the running was completed,  the gel was 
transferred onto 3 MM paper and dried under a vac-
uum.  The dried gel was then visualized by autora-
diography using a BioImaging Analyzer FLA-5000 
(Fuji Film,  Tokyo,  Japan).
　 Chromatin immunoprecipitation (CHIP) 
assay. CHIP assays were performed using a chro-
matin immunoprecipitation assay kit (Upstate Bio-
technology,  Lake Placid,  NY,  USA) according to the 
manufacturerʼs protocol [25,  28].  Brieﬂy,  ROS17/ 
2.8 cells were inoculated at a density of 5×106 per 
100-mm dish.  The cells were ﬁxed in a ﬁnal concen-
tration of 1ｵ formaldehyde for 10min at room tem-
perature.  After washing twice with PBS,  the cells 
were removed from dishes in PBS containing 1mM 
EDTA and harvested by centrifugation at 1,000g for 
1min at 4℃.  The cell pellets were resuspended in 
SDS lysis buﬀer,  incubated for 10min at 4℃,  and 
sonicated four times for 10sec,  yielding DNA frag-
ments 200-1,000bp in length.  After centrifugation,  
the supernatant was diluted in CHIP dilution buﬀer,  
precleared with ssDNA/protein A-agarose slurry,  and 
immunoprecipitated with the anti-Sp1 or anti-Sp3 
(Santa Cruz Biotechnology) antibodies overnight at 
4℃.  Immunocomplexes were captured on the 
ssDNA/protein A-agarose slurry and washed with a 
low-salt wash buﬀer,  a high-salt wash buﬀer,  and LiCl 
wash buﬀer.  Then they were washed twice with TE 
buﬀer.  The immunocomplexes were eluted by incuba-
tion for 15min at 25℃ with 200µl of elution buﬀer 
(1ｵ SDS,  100mM NaHCO3,  1mM dithiothreitol).  
To reverse the cross-linking of DNA,  the eluates 
were treated with 8µl of 5 M NaCl and incubated for 
4h at 65℃,  followed by treatment with proteinase K 
for 1h at 45℃.  The DNA fragments were extracted 
with phenol/chloroform and precipitated with ethanol.  
PCR was carried out for 40 cycles using a step cycle 
of 94℃ for 30sec,  55℃ for 20sec,  72℃ for 30sec,  
and 72℃ for 8min.  The sets of primers are listed in 
Table 1.  The PCR products were analyzed by elec-
trophoresis on 1.5ｵ ethidium bromide-stained agarose 
gel.
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　 DNA sequencing. Nucleotide sequences were 
determined by automated DNA sequencing (ABI 
PRISM 310 Genetic Analyzer,  Applied Biosystems,  
Foster City,  CA,  USA) using the BigDye Termi-
nator Cycle Sequencing Kit (Applied Biosystems).
Results
　 RNA expression of Col5a3 in cultured cells.
Initially,  the expression of the Col5a3 was examined 
in various cultured cells using the RT-PCR technique.  
As shown in Fig.  1A,  the predicted band was 
observed in ROS17/2.8 and MC3T3-E1 cells,  but not 
in RCS cells.  The PCR products were veriﬁed by a 
nucleotide sequence to conﬁrm the speciﬁcity of the 
ampliﬁed Col5a3 sequence.  A real-time RT-PCR 
experiment showed the expression to be higher in 
ROS17/2.8,  thus corresponding to mature osteo-
blasts,  than in MC3T3-E1,  which correspond to 
preosteoblastic cells (Fig.  1B).
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Fig. 1　 A,  RNA expression of Col5a3 in various cell lines.  RT-PCR analysis was performed on total RNA from ROS17/2.8,  MC3T3-E1,  
and RCS cell lines.  β-actin was included as a positive control for PCR; B,  A real-time RT-PCR was performed using ROS17/2.8 and 
MC3T3-E1 cells.  The relative expression of Col3a5 was normalized against that of the GAPDH gene.  The data are the mean ± S.D.  of 
three independent experiments.  The asterisks indicate statistically signiﬁcant results (p＜0.05); C,  A comparative sequence analysis of the 
Col5a3 promoter regions.  The dashes and asterisks indicate the same nucleotides as those of the mouse and missing nucleotides in 
comparison to those of other species.  The transcription start site positions of mouse Col5a3 and human COL5A3 are shown with arrows 
above.  The bold lines indicate cis-elements in the mouse promoter described in this paper.  The ATG codon of the translation start site is 
indicated with a box.  The putative repressor binding sites described previously in the human gene [22] are underlined.  (The GenBank 
accession numbers for the nucleotide sequence of pro-α3(V) collagen genes: mouse NT-039472,  human NT-011295,  rat NW-047798).
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　 The transcription initiation sites of Col5a3.
Oligo-nucleotide-capping RACE experiments were 
performed to determine the transcription initiation 
sites of Col5a3.  The oligo-nucleotide-capping RACE 
was carried out using total RNA derived from 
MC3T3-E1 cells.  Twenty independent clones were 
selected and sequenced.  The 5ʼ-ends of the Col5a3 
cDNA were located at 102bp upstream from the initi-
ating ATG codon,  and 15 of the 20 RACE products 
were generated from the same position,  thus suggest-
ing that the major transcription initiation site is 
located 102bp upstream from the initiating ATG 
codon (Fig.  1C).  The nucleotide sequence upstream 
from the major transcription initiation site is similar 
to those of the human and rat counterparts.  The 
Col5a3 promoter lacks a canonical TATA box and has 
a high GC content.
　 Functional analysis of the Col5a3 promoter 
region. To deﬁne the proximal regulatory regions 
in the Col5a3 promoter,  a series of chimeric con-
structs containing progressive 5ʼ ends linked to the 
luciferase gene were transfected into ROS17/2.8 and 
MC3T3-E1 cells,  which express the Col5a3 gene,  and 
into RCS cells,  which do not express that gene,  and 
luciferase assays were carried out (Fig.  2).  A higher 
activity level was observed in ROS17/2.8 cells,  while 
MC3T3-E1 cells showed moderate activity,  but there 
was almost no activity in RCS cells.  These results 
were consistent with those of the RT-PCR analysis 
(Fig.  1A and 1B).  The longest construct,  pGL4.10
－1824/＋92,  had a strong transcriptional activity,  
and deletion to the －337bp still showed strong tran-
scriptional activity in ROS17/2.8 cells and 
MC3T3-E1 cells.  The deletion to －141bp began to 
decrease the activity,  and deletion to the ＋1 showed 
almost a complete loss of luciferase activity in both 
cell lines.  These results indicate that the region 
between the －337 and ＋1bp is important for basal 
transcriptional activity of the Col5a3 promoter in 
osteoblastic cells.
　 Identiﬁcation of nuclear factor binding sites 
in the core promoter of the Col5a3. EMSA 
experiments were conducted to investigate the binding 
of nuclear proteins to the proximal Col5a3 promoter.  
Five overlapping oligonucleotide probes covering the 
region between －370 and －1bp were prepared based 
on the luciferase experiment data (Fig.  2).  The 
nuclear protein was prepared from ROS17/2.8 cells 
because they had the highest activity.
　 The －230/－141 and －160/－71 probes could 
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Fig. 2　 Luciferase assay of the Col5a3 promoter.  A,  A schematic illustration of the 5ʼ-deletion constructs of the Col5a3 promoter; B,  
Luciferase activity in ROS17/2.8 (closed histogram),  MC3T3-E1 (light shaded histogram),  and RCS cells (dark shaded histogram).  Relative 
luciferase activities (%) were normalized against the activity of the pGL4.10 －337/＋92-Luc construct,  which is indicated with a box,  in 
ROS17/2.8.  All of the constructs were cotransfected with the pRL-TK vector as an internal control for transfection eﬃciency.  Data are the 
mean ± S.D.  of 4 independent experiments.
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bind nuclear protein extracted from ROS17/2.8 cells 
in a dose-dependent manner,  while the －370/－281,  
－300/－211,  and －90/－1 probes could not bind 
nuclear protein (Fig.  3A).  In the cold competition 
experiment,  the DNA-protein complex of the region 
－230 to －141bp disappeared completely in the pres-
ence of a 100-fold excess of unlabeled －230/－141 
probe,  but not in the presence of excess unlabeled 
－300/－211 and －160/－71 probes (Fig.  3B).  
Similarly,  the DNA-protein complex of the region 
－160 to －71 disappeared completely in the presence 
of a 100-fold excess of unlabeled －160/－71 probe,  
but not in the presence of excess unlabeled －230/
－141 and －90/－1 probes (Fig.  3B).  Therefore,  
these complexes were speciﬁc,  and the sites of the 
complex located were －210 to －160 and －140 to 
－90.
　 Six short oligonucleotide probes,  which covered 
－220 to －181,  －200 to －161,  －180 to －141,  
－160 to －121,  －140 to －101,  and －120 to －81,  
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(A) (C)
(B)
probe
probe
probe
Fig. 3　 EMSA analysis of the Col5a3 promoter; A,  Binding assay using overlapping probes in the Col5a3 promoter.  A schematic illus-
tration of the probes used for EMSA is shown in the upper panel.  The 32P-labeled －370/－281 (lanes 1-4),  －300/－211 (lanes 5-8),  －
230/－141 (lanes 9-12),  －160/－71 (lanes 13-16),  and －90/－1 (lanes 17-20) probes were incubated with or without (－) nuclear 
extracts (N.E.) from ROS17/2.8 cells; B,  Competition analysis using an excess of unlabeled oligonucleotides.  The 32P-labeled －230/－
141 and －160/－71 were incubated with nuclear extracts from ROS17/2.8 cells in the presence of a 100-fold excess unlabeled －300/－
211 (lane 3),  －230/－141 (lanes 4 and 8),  －160/－71 (lanes 5 and 9),  and －90/－1 (lane 10) probes,  respectively.  Control assays were 
performed without nuclear extracts (lanes 1 and 6),  and with nuclear extracts but without a competitor (lanes 2 and 7); C,  A competition 
analysis using an excess of unlabeled oligonucleotides that are shorter than those used in (B).  A schematic illustration of the probes used 
for EMSA is shown in the upper panel.  The 32P-labeled －230/－141 (lanes 1-5) and －160/－71 (lanes 6-10) were incubated with or 
without (－) nuclear extracts (N.E.) from ROS17/2.8 cells in the presence of 100-fold excess unlabeled －220/－181 (lane 3),  －200/－
161 (lane 4),  －180/－141 (lane 5),  －160/－121 (lane 8),  －140/－101 (lane 9),  and －120/－81 (lane 10) probes.  Control assays were 
performed without nuclear extracts (lanes 1 and 6) and with nuclear extracts but without a competitor (lanes 2 and 7).
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were prepared to further investigate the binding sites 
(Fig.  3C).  The complex of the region －230 to －141 
was competitively inhibited with corresponding excess 
unlabeled oligonucleotides of －220/－181 and －200/
－161,  but was not inhibited with －180/－141 (Fig.  
3C).  It was therefore understood that the binding site 
of the complex was －200 to －181.  The complex of 
the region －160 to －71 was competitively inhibited 
with the corresponding excess unlabeled oligonucle-
otides of regions －160/－121 and －140/－101,  but 
it was not inhibited with －120/－81 (Fig.  3C).  
These results indicated that another site of the com-
plex was located at －140 to －121.
　 Identiﬁcation of nuclear factors in the core 
promoter of Col5a3. A data-base analysis was 
conducted to identify the nuclear binding proteins in 
the core promoter of the Col5a3 (transfac. gbf. de/
TRANSFAC/).  The Sp1 binding site was recognized 
in the －200/－181 region,  and the CCAAT motif,  
which is recognized by transcription factors of CBF/
NF-Y and was proven to be in the core promoter of 
human COL5A3 [22],  was found in the －140/－121 
region.
　 A competition assay was conducted with 2 shorter 
probes,  －220/－161 and －160/－101 (Fig.  3D),  to 
conﬁrm these 2 complexes.  The binding band of the 
－220/－161 probe disappeared completely in the 
presence of a 100-fold excess of unlabeled －220/
－161 and the consensus Sp1-binding oligonucleotides,  
but not in the presence of excess unlabeled －220/
－161 mt and Spmt oligonucleotides (Fig.  3D).  The 
binding band of the －160/－101 probe disappeared 
completely in the presence of a 100-fold excess of 
unlabeled －160/－101 wt and the CBFwt oligonucle-
otide,  but not in the presence of excess unlabeled 
－160/－101 mt and CBFmt (Fig.  3D).  An interfer-
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(E)(D)
Fig. 3　 (continued); D,  A competition analysis using an excess of unlabeled mutated oligonucleotides.  The identical and mutated 
nucleotides are indicated by dots and italics,  respectively.  The 32P-labeled －220/－161wt (lanes 1-6) and －160/－101wt (lanes 7-12) 
were incubated with nuclear extracts (N.E.) from ROS17/2.8 cells in the presence of 100-fold excess unlabeled －220/－161wt (lane 3),  
－220/－161mt (lane 4),  Spwt (lane 5),  Spmt (lane 6),  －160/－100wt (lane 9),  －160/－101mt (lane 10),  CBFwt (lane 11),  and CBFmt 
(lane 12).  Control assays were performed without nuclear extract or competitors (lanes 1 and 7),  and with nuclear extract but without 
competitors (lanes 2 and 8); E,  Supershift analysis using speciﬁc antibodies.  The 32P-labeled －220/－161 (lanes 1-5) and －160/－101 
(lanes 6-10) were incubated with nuclear extracts from ROS17/2.8 cells anti-Sp1 (lane 3),  anti-Sp3 (lane 4),  and both of these (lane 5),  
anti-CBF-A/NF-YB (lane 8),  anti-CBF-B/NF-YA (lane 9) and anti-CBF-C/NF-YC (lane 10).  Control assays were performed without 
nuclear extract (lanes 1 and 6),  and with nuclear extract but without the antibody (lanes 2 and 7).  The bands of Sp1,  Sp3,  and CBF/
NF-Y binding are indicated by arrows.
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ence assay was performed using speciﬁc antibodies.  
As shown in Fig.  3E,  the DNA-protein complex in the 
－220 to －160 region was supershifted by anti-Sp1 
and anti-Sp3 antibodies.  The complex in the －160 to 
－100 was also supershifted by anti-CBF/NF-Y anti-
bodies,  namely anti-CBF-A/NF-YB,  anti-CBF-B/
NF-YA,  and anti-CBF-C/NF-YC.  Therefore Sp1,  
Sp3,  and CBF/NF-Y appeared to speciﬁcally interact 
with the Col5a3 promoter in ROS17/2.8 cells.
　 In vivo occupancy of the Col5a3 promoter by 
transcription factors. Next,  the binding of these 
transcription factors to Col5a3 in ROS17/2.8 cells was 
tested by performing chromatin immunoprecipitation 
(CHIP) experiments.  DNA-protein complexes were 
immunoprecipitated with antibodies,  the cross-links 
were reversed,  and the recovered DNA fragments 
were monitored by PCR using the primer set p1 and 
p2 for the －293 to －68 region in the proximal pro-
moter region of the Col5a3 gene.  As shown in Fig.  4,  
DNA fragments immunoprecipitated with polyclonal 
antibodies against Sp1/Sp3 and CBF/NF-Y were 
ampliﬁed by PCR,  whereas those immunoprecipitated 
with normal IgG were not.  Other sets of primers,  
p3/p4 and p5/p6,  which amplied segments that were 
located approximately 4kb upstream and downstream 
of Col5a3 promoter,  respectively,  were used as con-
trols.  Those primer sets did not amplify the DNA 
fragments immunoprecipitated with polyclonal antibod-
ies against Sp1/Sp3 and CBF/NF-Y.  These results 
indicate that Sp1/Sp3 and CBF/NF-Y speciﬁcally 
bind to the Col5a3 core promoter in vivo.
　 Functional assay of transcription factor-
binding sites in transient transfection experi-
ments. Identiﬁcation of potential binding sites for 
the transcription factors led to the question of 
whether or not these sites are involved in the activa-
tion of the Col5a3 promoter in ROS17/2.8 cells.  To 
test this hypothesis,  deletion reporter constructs were 
generated.  These constructs included two 5ʼ-step-wise 
deletions (－141/＋92-Luc and －59/＋92-Luc),  3 
internal deletions (del1-Luc,  del2-Luc,  and del3-Luc) 
and 3 site-directed mutations (mut1-Luc,  mut2-Luc,  
and mut3-Luc) using the －337/＋92-Luc wild con-
struct.  The mutation constructs were changed in the 
Sp1,  CBF/NF-1,  and both binding sites (Fig.  5A).  
The promoter activity decreased by approximately 
30ｵ in the constructs solely deleted or mutated in the 
Sp1 binding site (－141/＋92,  del1-Luc,  and mut1-
Luc),  whereas it decreased by nearly 50ｵ in the 
constructs changed in the CBF/NF-Y site (del2-Luc 
and mut2-Luc; Fig.  5A).  The activity further 
decreased in the constructs that were changed at both 
sites (－59/＋92-Luc,  del3-Luc,  and mut3-Luc),  but 
still maintained more than 40ｵ of their activity (Fig.  
5A).
　 Functional analysis of Sp1/Sp3 and CBF/
NF-Y in ROS17/2.8 cells. The roles of Sp1/
Sp3 and CBF/NF-Y in Col5a3 promoter activity were 
further examined by inhibiting their binding to the 
promoter.  The eﬀect of Sp1/Sp3 was examined using 
mithramycin A (100µM),  which recognizes GC-rich 
promoter regions and interferes with the binding of the 
Sp family [29].  The eﬀect of CBF/NF-Y was exam-
ined by the overexpression of the dominant-negative 
CBF-B/NF-YA subunits,  which interact with the 
CBF-A/NF-YB and CBF-C/NF-YC subunits to form 
CBF/NF-Y.  Mithramycin A decreased activity in the 
－337/＋92-Luc,  del2-Luc,  and mut2-Luc constructs,  
which contain the Sp1 binding site,  but had no eﬀect 
on －141/＋92-Luc,  －59/＋92-Luc,  del1-Luc,  del3-
Luc,  mut1-Luc,  and mut3-Luc,  which do not contain 
that site (each lane 2 in Fig.  5B).  The overexpression 
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Fig. 4　 Chromatin immunoprecipitation analysis.  A CHIP assay 
was performed to conﬁrm the binding of Sp1/Sp3 and CBF/NF-Y to 
the Col5a3 promoter in vivo.  Lane 1,  immunoprecipitation without 
the antibody; Lane 2,  immunoprecipitation with the mixture of 
polyclonal antibodies against Sp1 and Sp3; Lane 3,  immunopre-
cipitation with the mixture of polyclonal antibodies against CBF-A/
NF-YB,  CBF-B/NF-YA,  and CBF-C/NF-YC; Lane 4,  immunopre-
cipitation with normal IgG.  All immunoprecipitated DNA fragments 
were analyzed by PCR with the indicated primers.
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of the dominant-negative CBF-B/NF-YA subunits also 
decreased the activity of －337/＋92-Luc,  －141/
＋92-Luc,  del1-Luc,  and mut1-Luc,  which contain the 
CBF/NF-Y binding site,  but had no eﬀect on －59/
＋92-Luc,  del2-Luc,  del3-Luc,  mut2-Luc and mut3-
Luc,  which do not contain that site (each lane 3 in 
Fig.  5B).
　 In addition,  Sp1 and Sp3 were overexpressed with 
the expression plasmids pCMV-Sp1 and pCMV-Sp3.  
The results,  in Fig.  6A,  conﬁrmed the increased 
expression of Sp1 and Sp3 mRNA in RT-PCR.  
Furthermore,  Fig.  6B shows that overexpression of 
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Fig. 5　 A functional analysis using deletion and mutation constructs of the Col5a3 promoter activity; A,  Left panel: A schematic illus-
tration of constructs that are mutated in putative nuclear protein binding sites in the Col5a3 proximal promoter.  Right panel: Luciferase 
activities in ROS17/2.8 cells transfected with the －337/＋92-Luc,  －141/＋92-Luc,  －59/＋92-Luc,  del1-Luc,  del2-Luc,  del3-Luc,  mut1-
Luc,  mut2-Luc,  and mut3-Luc constructs.  All of the constructs were cotransfected with pRL-TK vector as an internal control for transfec-
tion eﬃciency.  Relative luciferase activities (%) were normalized against the activity of the －337/＋92-Luc construct indicated with a box.  
Data are the mean ± S.D.  of 4 independent experiments.  The asterisks indicate statistically signiﬁcant results (p＜0.05); B,  A functional 
analysis by inhibition of the binding of Sp1/3 and CBF/NF-Y.  ROS17/2.8 cells were transfected with 0.5μg of －337/＋92-Luc,  －141/
＋92-Luc,  －59/＋92-Luc,  del1-Luc,  del2-Luc,  del3-Luc,  mut1-Luc,  mut2-Luc and mut3-Luc.  The cells were treated with mithramycin A 
(100nM; shaded histogram),  cotransfected with 1.5μg mutant CBF/NF-Y expression vector (striped histogram),  and treated with mith-
ramycin A after cotransfection of 1.5μg mutant CBF/NF-Y expression vector (closed histogram).  The empty vector was cotransfected as a 
control in each group (open histogram).  All of the constructs were cotransfected with pRL-TK vector as an internal control for transfection 
eﬃciency.  The relative luciferase activities (%) were normalized against the activity of the control.  Data are the mean ± S.D.  of 3 inde-
pendent experiments.  Asterisks indicate statistically signiﬁcant results (p＜0.05).
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Sp1 increased the activity of －337/＋92-Luc,  del2-
Luc,  and mut2-Luc (lane 2 in each construct),  while 
the overexpression of Sp3 had almost no eﬀect on 
activity (lane 3 in each construct).  The overexpres-
sion of Sp1 or Sp3 had no eﬀect on －141/＋92-Luc,  
－59/＋92-Luc,  del1-Luc,  del3-Luc,  mut1-Luc,  and 
mut3-Luc,  which do not contain the Sp1 binding site.
Discussion
　 Fibrillar collagen plays a key role in regulating 
bone mineralization and bone integrity [30].  A previ-
ous study showed the pro-α3(V) collagen chain to be 
expressed in bones such as the calvaria,  vertebra,  
maxilla,  mandibula,  and clavicula [17].  In the verte-
bral region,  pro-α3(V) was detected in the periosteum 
and bone matrix,  where ossiﬁcation initially occurs.  In 
the current study,  the promoter region was character-
ized by a transfection assay using a luciferase 
reporter gene and EMSA to understand the tran-
scriptional regulation of the Col5a3 gene in osteoblas-
tic cells.  Basal transcriptional activity was seen from 
－337 to ＋1 in premature and mature osteoblastic 
cells,  but not in chondrocytic cells.  A GC box and a 
CCAAT box in the region were critical binding sites 
for nuclear protein.  The Sp1/Sp3 bound to the GC 
box and CBF/NF-Y bound to the CCAAT box both in 
vitro and in vivo.  Furthermore,  a functional analysis 
by transfection with luciferase constructs showed that 
Sp1 and CBF/NF-Y were necessary for the basal 
transcriptional activity of the mouse Col5a3 gene in 
osteoblastic cells (Fig.  7).
　 The gene transcription is controlled by a series of 
complex interactions of many transcription factors.  
Among the collagen genes,  the transcriptional regula-
tion of type I collagen has been the most extensively 
studied,  and shows common features of the proximal 
promoter and tissue-speciﬁc enhancer.  Previous stud-
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Fig. 6　 A functional analysis by the overexpression of Sp1 and Sp3; A,  RT-PCR was performed with total mRNA from ROS17/2.8 cells,  
which were transfected with the overexpression vector of Sp1 (lane 2) and Sp3 (lane 3).  The empty vector was transfected as a control 
(lane 1); B,  ROS17/2.8 cells were transfected with 0.5μg of pGL4.10 －337/＋92-Luc,  －141/＋92-Luc,  －59/＋92-Luc,  del1-Luc,  del2-
Luc,  del3-Luc,  mut1-Luc,  mut2-Luc and mut3-Luc.  Cells were cotransfected with 1.5μg of Sp1 expression vector (lane 2),  Sp3 expres-
sion vector (lane 3),  and an empty vector as a control (lane 1).  All of the constructs were cotransfected with pRL-TK vector as an internal 
control for transfection eﬃciency.  The relative luciferase activities (%) were normalized against the activity of the control.  Data are the 
mean ± S.D.  of 3 independent experiments.  Asterisks indicate statistically signiﬁcant results (p＜0.05).
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ies have identiﬁed the Sp1,  Sp3,  and CBF/NF-Y 
binding factors for basal activity in both type I colla-
gen genes [31-33].  Other transcription factors,  such 
as c-Krox,  BFCOL1,  and IF-1,  are also reported in 
the regulation of type I collagen [34-36].  Type III 
collagen expression patterns are similar to those of 
type I collagen.  However,  the transcription factors 
involved seem to be diﬀerent from those of type I col-
lagen genes [37-39].  Sox9 binds to and activates the 
collagen genes that are speciﬁcally expressed in the 
chondrocyte,  such as Col2a1 and Col11a2 [40,  41].  
L-Sox5 and Sox6,  which share 50ｵ identity with 
Sox9 in the Sox domain,  are expressed downstream of 
Sox9 [42].
　 A previous report demonstrated that CBF/NF-Y 
and 2 repressors regulate the core promoter of the 
human COL5A3 gene in schwannoma cells [22].  
CBF/NF-Y is involved in transcriptional activity in 
osteoblastic cells in the mouse counterpart gene,  as 
expected from the conservation of the CCAAT-motif 
and ﬂanking sequence among species (Fig.  1B).  
CBF/NF-Y might be required to coordinate the 
expression of type I and V/XI collagen in noncarti-
laginous tissues [19,  25,  43-45].  However,  no 
repressors were identiﬁed in the current study.  This 
may be due to the diﬀerence in the binding sites of 
speciﬁc sequences (Fig.  1B) or cells.  Instead,  the 
current study found the Sp family to upregulate the 
gene in osteoblastic cells.  Sp1 and Sp3 are closely 
related proteins with very similar structural features 
[46].  They bind to the GC box with the same speci-
ﬁcity and aﬃnity and regulate gene transcription [24].  
Sp3 can either activate or repress the transcription of 
target genes depending on the cell type,  based on the 
context of DNA binding sites,  and the interactions 
with other nuclear factors [47].  Sp1 and Sp3 bind to 
the promoter in the current study.  However,  only Sp1 
increased the activity of the Col5a3 promoter in osteo-
blastic cells.  Sp3 might therefore not aﬀect the 
expression of the Col5a3 gene.
　 Deletions and/or mutations that removed the bind-
ing sites of both Sp1 and CBF/NF-Y did not com-
pletely eliminate the promoter activity.  This sug-
gested that other factors or mechanisms are involved 
in the activation of the Col5a3 gene in bone tissues.  In 
the α1(I) collagen gene,  Runx2/Cbfa1,  which is 
regarded as the master transcription factor for osteo-
blast diﬀerentiation [48-50],  bound at approximately 
－1347bp of the rat,  mouse,  and human genes of the 
promoter [51].  In the current study,  although the 
binding of Runx2/Cbfa1 to the Col5a3 promoter has 
not yet been demonstrated,  such factors may therefore 
also be responsible for the activation of the Col5a3 
gene.  Further study will provide some valuable insight 
regarding the involvement of type V collagen in bone 
formation.
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